Compromised quality of life in adult patients who have received a radiation dose towards the basal part of the brain. A case-control study in long-term survivors from cancer in the head and neck region

Table 1 Patient characteristics, treatment and, radiotherapy doses in growth hormone sufficient adults who have received a radiation dose towards the basal part of the brain ¹

Pat no	Sex and age	Diagnose/tumour stage	Chemo-therapy	Tumour BT Boost (Gy)	Tumour/ Neck (r-l) EBRT Dose (Gy)	Hypo- thalamus EBRT + BT* Dose (Gy)	Pituitary EBRT + BT Dose (Gy)
1	m 32	Tonsil /T1N0M0	No	25	40.8 /40.8-0	0.9 + 0.7 =1.6	1.3 +0.7= 2.0
2	m 56	Tonsil/T3N3M0	Yes	12	64.6 /64.6-40.8	1.6 + 0.3 = 1.9	2.2 +0.3 = 2.5
3	f 53	Tonsil/T2N0M0	No	27	40.8 /40.8-40.8	1.1 + 0.7 = 1.8	1.3 +0.8 = 2.1
4	f 51	Epipahr/T2N1M0	Yes	6	61.2 /61.2-40.8	8.1 + 1.2 = 9.3	44.2 +1.9 = 46.1
5	m 50	Tonsil/T1N1M0	Yes	25	40.8 /40.8-64.6	1.2 + 0.7 = 1.9	1.7 +0.7 = 2.4
6	m 66	Epipahr/T2N0M0	No	6	61.2 /40.8-40.8	4.8 + 1.2 = 6.0	31.6 +1.9 = 33.5
7	m 55	Tonsil/T3N0M0	Yes	15	64.6 /40.8-40.8	1.8 + 0.4 = 2.2	2.3 +0.4 = 2.7
8	f 54	Tonsil /T2N2M0	Yes	27	40.8 /40.8-64.6	1.2 + 0.7 = 1.9	1.7 +0.8 = 2.5
9	m 55	Tonsil/T3N0M0	Yes	12	64.6 /40.8-40.8	1.5 + 0.3 = 1.8	2.1 + 0.3 = 2.4
10	m 59	Orophar/T2N0M0	No	0	50.0 /50.0-50.0	2.0 + 0 = 2.0	2.7 + 0 = 2.7
11	m 58	Necklgl/TxN1M0	Yes	0	64.6 /40.8-64.6	2.0 + 0 = 2.0	3.3 + 0 = 3.3
12	m 65	Tonsil/T4N0M0	Yes	12	64.6 /40.8-40.8	1.2 + 0.3 = 1.5	1.9 + 0.3 = 2.2
13	m 66	Tonsil/T2N2M0	Yes	12	64.6 /40.8-64.6	1.5 + 0.3 = 1.8	2.1 + 0.3 = 2.4
14	f 63	Tonsil/T2N0M0	No	26	40.8 /40.8-40.8	0.8 + 0.7 = 1.5	1.0 + 0.8 = 1.8
15	m 61	Tonsil/T4N0M0	Yes	12	64.6 /40.8-40.8	2.0 + 0.3 = 2.3	2.6 + 0.3 = 2.9

¹Abbreviations: BT = brachytherapy, r = right side of neck, l = left side of neck, EBRT = external beam radiotherapy, m = male, f = female.
* The brachytherapy dose contribution was estimated to be 1.2 Gy to the hypothalamus and 1.9 Gy to the pituitary for patients 4 and 6. For all other patients, brachytherapy doses to the hypothalamus was 2.7% and to the pituitary 2.9%, estimated from calculations performed on 6 patients with cancer in the tonsil.

ISSN: 1748-717X